OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
OPRXWALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company’s Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company’s leadership bench and CEO Steve Silvestro’s commitment to aligning talent and structure with OptimizeRx’s long-term strategic objectives under his management.
OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance
OPRXWALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are to the same year-ago period.
Stifel Maintains Buy on OptimizeRx, Raises Price Target to $16
OPRXWatching OptimizeRx; Hearing Zacks Homerun Newsletter Picks Stock
OPRXStifel Maintains Buy on OptimizeRx, Raises Price Target to $12.5
OPRXJMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $14
OPRXOptimizeRx Raises FY2025 Sales Guidance from $100.00M to $101.00M-$106.00M vs $101.26M Est
OPRXOptimizeRx Q1 Adj. EPS $0.08 Beats $(0.12) Estimate, Sales $21.93M Beat $18.69M Estimate
OPRXOptimizeRX Corp Files For Mixed Shelf Of Up To $75M
OPRXOptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million
OPRXOptimizeRx reports sales of $32.32M in Q4, beating consensus, with adjusted EPS of $0.30. Full-year revenue increased 29% and EBITDA grew 53%.
OptimizeRx Corporation Shares Resume Trading; Up 54%
OPRXOptimizeRx Shares Halted On Circuit Breaker To The Upside, Stock Now Up 53.1%
OPRXOptimizeRx Sees FY25 Adjusted EBITDA Of At Least $12M
OPRXOptimizeRx Sees FY25 Revenue Of At Least $100M Vs. $99.646M Est.
OPRXOptimizeRx Q4 Adj $0.30 Beats $0.27 Estimate, Sales $32.32M Beat $30.36M Estimate
OPRXOptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer, Effective Mar. 10
OPRXLake Street Reiterates Buy on OptimizeRx, Maintains $11 Price Target
OPRXOptimizeRx CEO William Febbo To Depart, Announces Appointment Of Stephen Silvestro As Interim CEO, Effective As Of December 31, 2024
OPRXThe Analyst Verdict: OptimizeRx In The Eyes Of 6 Experts
OPRXStephens & Co. Initiates Coverage On OptimizeRx with Equal-Weight Rating, Announces Price Target of $5.5
OPRXRBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $7
OPRXRoth MKM Reiterates Buy on OptimizeRx, Lowers Price Target to $16
OPRXStifel Maintains Buy on OptimizeRx, Lowers Price Target to $8
OPRXBarclays Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $5
OPRXJMP Securities Maintains Market Outperform on OptimizeRx, Lowers Price Target to $8
OPRXOptimizeRx Reaffirms FY22 Guidance, Sales $80M-$85M Vs 81.83M Est.
OPRXOptimizeRx Q1 EPS $(0.01), Inline, Sales $13.70M Miss $13.97M Estimate
OPRX